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Abstract: Tight glycaemic control (TGC) in critical care has shown distinct benefits, but has also proven 
difficult to obtain. The risk of severe hypoglycaemia (< 2.2mmol/L) raises significant concerns for safety. 
Continuous Glucose Monitors (CGMs) offer frequent, though potentially noisy, automated measurement 
and thus the possibility of using them for early detection and intervention of hypoglycaemic events. This 
in-silico study investigates the potential of CGM devices to maintain control, prevent hypoglycaemia and 
reduce clinical effort. Retrospective clinical data from the SPRINT TGC study covering 26 patients was 
used with clinically validated metabolic system models and 3 different stochastic noise models (two 
Gaussian and one first-order autoregressive.) The noisy, virtual CGM blood glucose (BG) values were 
filtered and used to drive the SPRINT TGC protocol. A simple threshold alarm was used to trigger 
glucose interventions to avert potential hypoglycaemia. Monte Carlo analysis was used to get robust 
results from the stochastic noise models. Using SPRINT with simulated CGM noise, the BG time in the 
4.4-6.1mmol/L band was reduced no more than 3% from 45.2% obtained with glucometer sensors. The 
number of patients experiencing severe hypoglycaemia was reduced by 0-30%. Duration of 
hypoglycaemic events was reduced by 19-65%. Finally, nurse workload was reduced by approximately 
20 minutes per patient, per day. The results of this proof of concept study justify a pilot clinical study for 
verification in a clinical setting. 
Keywords: Hypoglycaemia, CGM, continuous glucose monitor, alarm, glycaemic control, blood glucose, 
sensor. 
1. INTRODUCTION 
Critically ill patients often experience high levels of insulin 
resistance and stress-induced hyperglycaemia, (Finney et al., 
2003, Krinsley, 2004) which can negatively impact outcomes 
(Capes et al., 2000, Finney et al., 2003). Some studies have 
shown that tight glycaemic control (TGC) can reduce 
intensive care unit (ICU) patient mortality by up to 45% (Van 
den Berghe et al., 2001, Krinsley, 2004, Chase et al., 2008c). 
Although there is little agreement on what constitutes 
desirable glycaemic performance (Mackenzie et al., 2005), 
the primary aim of TGC is to reduce elevated blood glucose 
with minimal hypoglycaemia. Two major causes of 
hypoglycaemia are reported to be clinical error and/or 
infrequent BG measurement using bedside glucometers or 
blood gas analysers (Chase et al., 2008a, Braithwaite et al., 
2006).  
Typically, in most ICU studies blood glucose is measured 1-4 
hourly and more frequently only if the levels are already at or 
near hypoglycaemia. More frequent measurement (even 1-2 
hourly) is uncommon due to the clinical effort required. The 
result can be extremely variable glycaemic control with 
longer measurement intervals. Thus, continuous glucose 
monitors (CGMs) with their rapid 2-10 minute measurement 
rates may allow more tightly controlled BG levels. 
There have been relatively few successful investigations of 
CGMs in critical care use (Goldberg et al., 2004). Added 
sensor noise is a trade off (in some cases) of the CGMs far 
higher, automated sampling rate (Goldberg et al., 2004, 
Clarke et al., 2005) and excess sensor noise must be 
effectively managed. However, these sensor and algorithm 
technologies are also constantly evolving, with every new 
generation offering improvements (Klonoff, 2005).  
This study examines how ICU patients might behave on the 
SPRINT TGC protocol driven by simulated CGM 
measurements rather than the normal 1-2 hourly glucometer 
measurements. Hypoglycaemia detection and prevention are 
also tested, as CGMs offer the ability to detect and avert 
these events. This in-silico study thus aims to demonstrate 
that CGM devices coupled with an effective TGC protocol 
are capable of reducing nursing workload, and increasing 
safety, while maintaining TGC. 
2. SUBJECTS AND METHODS 
2.1 Subjects: 
This study uses retrospective clinical data from 26 patients, 
comprising of the 20 patient benchmark cohort from the 
SPRINT TCG study (Chase et al., 2008b) and 6 additional 
SPRINT patients who experienced at least one genuine  
hypoglycaemic event during their stay. SPRINT is a TGC 
  
     
 
protocol implemented in Christchurch ICU since August 
2005 that modulates both insulin and dextrose nutrition. BG 
data is sampled 1-2 hourly using bedside devices via either 
arterial line or fingerstick. Each patient spent 5 days or longer 
on SPRINT, during which time some experienced breaks in 
treatment, typically due to surgery or other clinical changes. 
Patients who experienced breaks from SPRINT had their BG 
data segmented into 2 or more un-interrupted episodes (at 
least 12 hours), resulting in 55 individual continuous data 
sets. Each episode was then treated as an individual ‘patient’ 
for the purposes of this study. Details of the patient cohort are 
shown in Table 1. The use of these patient records falls under 
existing ethics approval granted by the Upper South Regional 
Ethics Committee, New Zealand. 
Table 1. Cohort details, presented as median [inter-
quartile range] where applicable. 
Number of Patients, N 55 
Age 
66 
[59 - 73] 
Gender 65% Male 
Length of SPRINT (hours) 
139 
[42 - 210] 
Number of clinical Measurements 
77 
[27 - 146] 
APACHE II Score 
20 
[15 - 27] 
APACHE II risk of death (%) 
33.6 
[13.7 - 56.1] 
2.2 Methods – Insulin-Glucose Regulatory System Model: 
This study uses a model derived from the clinically validated 
glucose-insulin model reported in (Lin et al., 2008a). 
Modifications to the model include removal of the basal set 
point term due to the difficulty of obtaining it for critical care 
patients, and, addition of endogenous glucose production 
(EGP) and central nervous system (CNS) uptake. Finally, a 2 
compartmental feed model was used to ensure mass 
conservation of ingested glucose. 
2.3 Methods – CGM Noise Models: 
This study uses two different types of stochastic noise model. 
One simple, Gaussian model based on data from an ICU trial 
of CGM sensors (Goldberg et al., 2004), and one first-order 
autoregressive model based on an analysis of data from 
individuals with ambulatory type 1 diabetes (Breton and 
Kovatchev, 2008).  
Two levels of Gaussian noise model are investigated. The 
first is designed to produce equivalent simulated CGM BG 
measurement errors on a similar cohort to those reported in 
(Goldberg et al., 2004) in a 2004 study of the Medtronic 
CGMS (Minimed-Medtronic, Northridge, CA) device in a 
medical ICU. The second Gaussian model had the magnitude 
of additive noise reduced by half to simulate improvements in 
technology since 2004. Both models used independent, 
identically distributed Gaussian based noise as described in 
(Pretty et al., 2010). 
The autoregressive noise model implemented in this paper is 
that described in (Breton and Kovatchev, 2008) in their 2008 
study of CGM error in ambulatory type 1 diabetics. This 
model is based on data from the FreeStyle Navigator CGM 
sensor (Abbott Diabetes Care, Alameda, CA). The model 
consists of two parts, a delay modelling the diffusion time 
from plasma to interstitium and sensor lag, and non-Gaussian 
sensor noise. The sensor noise is modelled as first-order 
autoregressive with the random component taken from an 
unbounded Johnson system as reported in (Breton and 
Kovatchev, 2008).  
Figure 1 compares the error distributions obtained on this 
cohort for each of the error models used in this study. The 
distributions for the Breton and Goldberg-half magnitude 
models are very similar despite their time-series behaviour 
being quite different. However, the similarity does show a 
measure of technological advancement since the original 
Goldberg study (Goldberg et al., 2004). 
Calibration drift due to sensor degradation over time was not 
considered in this study, as this factor is controlled by the 
specific calibration protocol used with the sensor and has not 
been reported in detail to the authors knowledge. 
2.4 Methods – In-Silico CGM Measurements: 
Model generated blood glucose profiles for each patient were 
sampled incrementally at 5 minute intervals. As these ‘actual’ 
BG measurements were sampled in-silico, noise was added 
from a noise model, creating incremental virtual CGM 
measurement sequences.  
2.5 Methods – CGM Filtering:  
The virtual CGM sensor BG measurements and error were 
implemented using MATLAB™ (The Mathworks; Natick, 
MA). The noisy measurements were filtered incrementally, 
simulating the process that would be encountered in a real-
 
-4 -3 -2 -1 0 1 2 3 4
0
0.01
0.02
0.03
0.04
0.05
0.06
 
 
Breton noise model
Goldberg full noise model
Goldberg half noise model
D
en
si
ty
 
BG measurement error (mmol/L) 
Figure 1. Error distributions of noise models used in this 
study. 
  
     
 
time clinical setting. A median filter as described in (Pretty et 
al., 2009) was used in this study.  
2.6 Methods – Hypoglycaemia Alarm/Intervention Design: 
This study used a simple threshold algorithm to trigger an 
alarm and glucose intervention when a hypoglycaemic event 
appeared imminent. The criteria for triggering an alarm and 
intervention were: 
 Two consecutive CGM measurements < 3mmol/L 
 A negative BG gradient. 
 At least 15 minutes since the last intervention 
Two different sized glucose interventions were used in this 
study. A 12.5 gram intra-venous (IV) bolus was given over 3 
minutes, unless a SPRINT BG measurement (1-2 hourly) had 
been taken in the previous 15 minutes. If a SPRINT 
measurement had been taken, the size of the bolus was 
reduced to 6 grams, to reduce interference with any increase 
in nutritional prescribed by the protocol. The 15 minute 
period between consecutive interventions replicates typical 
clinical practice, allowing time to see a significant outcome 
BG change. 
2.7 Methods – Simulating SPRINT with CGM Measurements: 
A single filtered measurement was taken 1-2 hourly from the 
full sequence of filtered CGM data and used to drive the 
SPRINT protocol, with no other modifications to the 
algorithm. Thus, using CGM with all else equal would save 
significant nursing time by removing the need for a finger 
stick measurement every 1-2 hours (mean 16/day) (Chase et 
al., 2008c). While the SPRINT protocol only used 1-2 hourly 
values from CGM sequence, the full set of data was used for 
the hypoglycaemia detection and prevention part of the study. 
2.7 Methods – Analysis: 
Monte Carlo simulations were performed using the three 
stochastic noise models, with 10 runs for each  of the 55 BG 
episodes. The baseline simulation (no added noise) was 
performed once, for comparison. 
Time in the 4.4-6.1mmol/L BG band and time spent in 
hypoglycaemia (below 2.2mmol/L) were considered the most 
important metrics for this investigation. These metrics were 
calculated using two different methods. The first method used 
only the 1-2 hourly filtered CGM measurements driving 
SPRINT, allowing a fair comparison with the clinical data. 
The second method used the full, continuous CGM data 
sequence to simulate what might be seen in a clinical 
situation if CGMs were used.  
Nutrition and insulin interventions prescribed by SPRINT 
were also examined. Differences in these interventions 
compared to the baseline SPRINT results were analysed to 
determine the impact of CGM sensor noise on operation of 
this protocol.  
Results are presented as non-parametric (median 
[interquartile range]) or lognormal (mean [1 standard 
deviation range]) as indicated. Lognormal statistics reflect the 
skewed (non-Gaussian) results obtained for BG levels. 
3. RESULTS 
Tables 2, 3, 4 and 5 show the level of control that was 
achieved when each of the noise models was implemented. 
Results in Tables 2, 3 and 4 were determined using only the 
1-2 hourly SPRINT BG measurements, allowing a fair 
comparison with the clinical baseline results. Table 5 shows 
Summary Statistics Clinical Baseline Breton Goldberg (full) Goldberg (half)
Num 1-2 hourly BG measurements [IQR]: 5816 5923 [5897 - 5948] 5978 [5974 - 5988] 5822 [5811 - 5855]
BG median [IQR] (mmol/L): 5.6 5.6 [4.7 - 6.6] 5.7 [4.7 - 6.6] 5.6 [4.7 - 6.5]
% BG within 4.4-6.1 mmol/L [IQR] 45.2 43.4 [43.3 - 43.8] 42.4 [42.2 - 42.6] 46.1 [45.2 - 46.3]
Median insulin rate [IQR] (U/hr): 3.0 [2.0 - 3.0] 3.0 [1.0 - 3.0] 3.0 [1.0 - 3.0] 3.0 [2.0 - 3.0]
Median glucose rate [IQR] (g/hr): 5.2 [3.3 - 6.3] 5.2 [3.3 - 6.5] 5.2 [3.3 - 6.5] 5.2 [3.3 - 6.5]
Table 4. Per-patient summary statistics as reported by 1-2 hourly filtered CGM from Monte Carlo simulations using 
each of the noise models (with alarm and 12.5 gram interventions). 
Table 2. Overall cohort summary statistics as reported by 1-2 hourly filtered CGM from Monte Carlo simulations 
using each of the noise models (with alarm and 12.5 gram interventions). 
Table 3. Overall cohort hypoglycaemia/intervention statistics as reported by 1-2 hourly filtered CGM from Monte 
Carlo simulations using each of the noise models (with alarm and 12.5 gram interventions). 
Per-patient statistics Clinical Baseline Breton Goldberg (full) Goldberg (half)
Hours of control [IQR]: 137.0 [41.3 - 208.3] 138.0 [41.3 - 208.3] 137.0 [41.0 - 208.5] 137.0 [41.3 - 208.3]
Num 1-2 hourly BG measurements [IQR]: 79.0 [36.8 - 119.0] 82.0 [36.3 - 121.8] 82.0 [32.3 - 122.0] 82.0 [36.3 - 118.8]
BG median [IQR] (mmol/L) 5.8 [4.8 - 6.2] 5.8 [4.9 - 6.2] 5.8 [4.8 - 6.2] 5.8 [4.7 - 6.2]
% BG within 4.4-6.1 mmol/L [IQR] 41.7 40.0 [41.1 - 41.9] 39.0 [38.5 - 39.6] 42.3 [41.6 - 43.0]
Median insulin rate [IQR] (U/hr): 3.0 [1.2 - 3.0] 3.0 [2.0 - 3.0] 3.0 [1.2 - 3.0] 3.0 [1.2 - 3.0]
Median dextrose rate [IQR] (g/hr): 5.2 [3.4 - 6.5] 5.2 [3.3 - 6.5] 5.2 [3.3 - 6.5] 5.2 [3.4 - 6.5]
Hypoglycaemia/Intervention statistics Clinical Baseline Breton Goldberg (full) Goldberg (half)
% BG < 4.4 mmol/L [IQR] 19.7 19.7 [19.4 - 19.8] 20.7 [20.5 - 20.7] 19.8 [19.7 - 19.9]
% BG < 2.2 mmol/L [IQR] 0.4 0.5 [0.5 - 0.6] 0.3 [0.3 - 0.4] 0.2 [0.2 - 0.3]
Num patients < 2.2 mmol/L [IQR] 12.0 12 [11 - 12] 10 [8 - 11] 8 [6 - 9]
Number of interventions (where applicable) 0 356 330 244
  
     
 
results determined using the entire CGM sequence (5 minute 
values), representing what might be observed in the clinical 
setting if CGM monitoring was implemented. The baseline 
data is provided for comparison, and is the model-generated 
BG profile (based on 1-2hourly clinical data). 
Table 2 shows that there are no clinically significant 
differences in the median BG levels between the baseline, 
Breton model, and Goldberg models. Time in the target 4.4-
6.1mmol/L band is also very similar between the baseline and 
CGM results and the differences are not considered clinically 
significant. Insulin and glucose administration remains 
unchanged with the addition of noise. 
Table 3 shows the number of patients experiencing at least 
one hypoglycaemic event appears dependent upon the noise 
model. When using the Breton model the number of patients 
experiencing hypoglycaemia is unchanged from the baseline 
(12 events). However, with the Goldberg-full and half 
magnitude models, the number of hypoglycaemic events is 
reduced to as low as 8 per run.  
The per-patient results in Table 4 are presented as a means of 
reducing the effect of very long stay patients on the overall 
results of the cohort. The results show similar trends to the 
overall cohort results and any differences seen are not 
clinically significant. 
In Table 5 the BG median for each of the noise models is 
very similar to the results seen for the baseline (no noise). 
Time in the 4.4-6.1mmol/L band has decreased 2-6% 
depending on the noise models and percent below 4.4mmol/L 
along with percent below 4mmol/L have increased slightly. 
Interestingly, percent below 2.2mmol/L has decreased for all 
3 error models, suggesting the interventions are reducing the 
time spent in hypoglycaemia. 
Figure 2 shows the BG profile for a patient who experienced 
severe hypoglycaemia. The top plot illustrates how a patient 
can become hypoglycaemic (739 hour) and remain there for 
approximately 1 hour, when not monitored by a CGM. The 
bottom plot shows the same patient being monitored by a 
CGM using the Breton noise model. Potential hypoglycaemia 
is detected prior to the 739 hour, and a 12.5 gram IV 
intervention is given, preventing a drop below 2.2mmol/L. 
4. DISCUSSION 
4.1 Performance: 
The aims of this in-silico study were to show that nursing 
workload can be reduced, the level of glycemic control 
maintained, and early hypoglycemic detection/prevention 
implemented using CGM sensors in the ICU, despite 
potentially high levels of sensor noise in individual 
measurements. The performance of the CGM sensors in this 
role was evaluated in-silico using Monte Carlo simulations 
with stochastic CGM noise models and real ICU patient data. 
Using CGMs to monitor BG levels in the ICU could improve 
patient safety by alerting nurses at the onset of potential 
hypoglycaemia. Early warning or detection of hypoglycaemia 
would allow it to be avoided or the length of the episode 
minimised.  
Figure 2. (Top) Blood glucose profile for a patient from the baseline simulation, showing a hypoglycaemic event at 
739 hours. (Bottom) Blood glucose profile for the same patient when controlled by a CGM using the Breton noise 
model. A hypoglycaemic event is detected, so 12.5gram intravenous glucose is given just before 739 hours, 
preventing hypoglycaemia. 
Summary Statistics (CGM) Baseline (no noise) Breton Goldberg (full) Goldberg (half)
BG median [IQR] (mmol/L): 5.5 5.7 [4.8 - 6.5] 5.7 [4.8 - 6.5] 5.6 [4.8 - 6.4]
% BG within 4.4-6.1 mmol/L [IQR] 53.9 47.9 [47.8 - 48.1] 47.1 [46.9 - 47.4] 51.9 [51.7 - 52.1]
% BG < 4.4 mmol/L [IQR] 15.5 16.3 [16.1 - 16.4] 17.1 [17.0 - 17.1] 15.4 [15.3 - 15.5]
% BG < 4 mmol/L [IQR] 8.7 9.2 [9.0 - 9.4] 9.7 [9.6 - 9.8] 8.2 [8.1 - 8.3]
% BG < 2.2 mmol/L [IQR] 0.28 0.23 [0.22 - 0.25] 0.15 [0.14 - 0.16] 0.09 [0.09 - 0.10]
Num patients < 2.2 mmol/L [IQR] 12 12 [11 - 12] 10 [8 - 11] 8 [6 - 9]
Table 5. Overall cohort summary statistics as reported by simulated 5 minute CGM from Monte Carlo simulations 
using each of the noise models (with alarm and 12.5 gram interventions). 
  
     
 
The lack of clinically significant changes in the blood glucose 
control metrics shown in Table 2 suggest that the additional 
noise introduced by the CGM sensors has little effect, at least 
in the context of the SPRINT protocol. This may be because 
SPRINT is model-derived and both the inputs and outputs are 
discretised, so small sensor errors do not generally have a 
large effect on the protocol selected insulin and nutrition rates 
and thus the resulting blood glucose levels.  
Table 3 shows that the median, mean and standard deviation 
BG levels are not clinically different between baseline and 
the modelled CGM results. The time in the 4.4-6.1mmol/L 
band was reduced by 2-7% with the CGM results compared 
to the baseline, but this may be clinically acceptable given the 
potential advantages of CGMs in reducing the number and 
duration of hypoglycaemic episodes. 
The number of patients experiencing severe hypoglycaemia 
did not increase from the baseline with the modelled CGM 
devices. The decrease in the number of hypoglycaemic events 
observed with the Goldberg models could be due to  the 
independent nature of each error about the current actual BG 
level, which does not take into account any delay or time-
series behaviour. This allows the alarm/intervention 
algorithm to detect and avert hypoglycaemic events earlier 
than the Breton model. This is dependent on the type of error 
models used, and could likely be resolved with real, ICU 
specific, CGM data. 
Table 3 shows that the total combined duration of severe 
hypoglycaemic events is reduced from 26 hours (9302 hours 
x 0.028%) to between 9 and 21 hours (total for 10 Monte 
Carlo runs) depending on the noise model. With CGM data 
the number of patients experiencing hypoglycaemia may not 
be reduced however the reduction in duration of the events is 
still a clinically significant result given their negative impact 
on outcome (Egi et al., 2010) 
A final significant result is the reflection on nursing time. 
SPRINT typically requires on average 16 measurements per 
day at 1.5 - 2 minutes per measurement (all tasks) (Lin et al., 
2008b). Assuming a CGM was implemented with a noise 
model similar to that of Breton et al, the alarm/intervention 
algorithm used in this study would require on average 1 
intervention per approximately 24 hours. With 4 calibration 
measurements per day and a single intervention, these results 
would reduce the total measurement burden 70% (11/day) or 
17-22 minutes per patient per day, which is potentially 
clinically significant in a busy ICU environment. 
4.2 Limitations - Clinical: 
Clinical testing is required to confirm the results of this in-
silico study, even though the virtual patient simulation 
method used here is clinically well validated (Chase et al., 
2007, Lonergan et al., 2006). The BG sequences used to drive 
SPRINT in this study were model-based, not real CGM 
output data. This analysis provides a strong initial proof of 
concept, however, testing and validation of the findings in a 
clinical setting is needed to confirm these results. 
4.2 Limitations – Signal Processing: 
Two separate stochastic noise models were used in this study 
providing 3 different CGM sensor noise profiles. The two 
Gaussian noise profiles are based on data from a study of 
CGMs in a medical ICU (Goldberg et al., 2004), however the 
model was created from reported sensor error statistics and 
therefore the time-series information about the errors is lost, 
hence they are assumed to be independent. The third noise 
profile was generated using the model reported in (Breton 
and Kovatchev, 2008), and while much more complete in 
terms of modelling glucose diffusion to the interstitium and 
the interdependence of errors, the model was derived for 
ambulatory type 1 diabetics and is therefore not necessarily 
the best model for ICU patients.  
While not having a validated, ICU-specific CGM noise 
model, analysing the results of these 3 noise profiles shows 
little difference in the overall control (mean, median and 
standard deviation) of the patients and it is therefore 
anticipated that real CGM characteristics are captured 
somewhere between these three simulated models.  
True sensor noise characteristics combined with more 
advanced filtering techniques would likely result in a much 
cleaner CGM data stream and hence a more reliable method 
for triggering alarms and interventions. The simple alarm 
algorithm may also have triggered false hypoglycemia alarms 
furthering the need for a more robust algorithm such as an 
integral-based method (Chase et al., 2006, Pretty et al., 2009). 
Thus, a better model would likely improve the performance 
outcomes and alarm data reported here. Hence, these results 
as presented are potentially conservative. 
Calibration drift due to sensor degradation over time was not 
considered in this study. Without correction, calibration drift 
will show up as though the actual BG measurements were 
higher or lower in a relatively consistent manner as the sensor 
gain drifts (Kuure-Kinsey et al., 2006). This drift would 
cause the alarm to trigger early (possibly falsely) or late. 
However, such calibration drift is typically a function of the 
frequency and quality of calibration measurements, which 
can likely be controlled more readily in a critical care setting 
using sensors such as blood gas analysers. This issue also has 
not been quantified, to date, in the critical care setting with 
modern CGM devices. 
4.5 Summary: 
Finally, this paper is focused on proof of concept for the 
integration of CGMs into the ICU. The generally good results 
seen here with sub-optimal filtering and a conservative noise 
model serve primarily to show that the method is feasible and 
deserves further direct clinical investigation. 
5. CONCLUSION 
This paper has analysed in-silico the use of CGM sensors 
with simple filters and hypoglycaemia alarms to provide 
input to the SPRINT TGC protocol. CGMs, even with 
considerable noise, have no significant clinical impact on 
TGC under the SPRINT protocol. CGMs could potentially 
reduce the number and duration of hypoglycaemic events 
with suitable alarm and intervention algorithms. Finally, the 
use of CGMs with SPRINT could reduce nursing burden for 
  
     
 
measurement up to 70%, potentially saving 17-22 minutes 
per patient, per day. All of these results justify clinical testing 
for validation, as well as highlighting the main issues in using 
CGMs for TGC in critical care. 
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